Objectives: To evaluate NMP22, BTA–Stat and BTA–Trak tests in monitoring recurrent transitional cell carcinoma of the bladder.Methods: The tests were performed in 179 selected patients being followed up for recurrent superficial bladder tumors: 55 patients had bladder recurrence and 124 patients were recurrence free. The NMP22 test was obtained in all patients; BTA–Stat and BTA–Trak in the last 96 and 74 patients, respectively. Sixty–four patients (51.6%) were undergoing adjuvant intravesical chemotherapy.Results: Sensitivity was 74, 57 and 62% and specificity was 55, 62 and 79% for NMP22, BTA–Stat and BTA–Trak, respectively. A high percentage of patients submitted to intravesical chemotherapy had false–positive tests. Positive predictive values of the NMP22, BTA–Stat and BTA–Trak tests were 42.2, 40 and 45.4%, and negative predictive values were 82.9, 76.9 and 88.4%, respectively.Conclusions: NMP22, BTA–Stat and BTA–Trak tests cannot replace cystoscopy and cannot be adopted as routine tools in surveillance after TUR in patients with superficial bladder cancer.